Protagonist Therapeutics Analyst Ratings
Protagonist Therapeutics Analyst Ratings
Buy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical Trials
Protagonist Therapeutics Analyst Ratings
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)
Protagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising Pipeline
Protagonist Therapeutics Earns 'Buy' Rating on Strong Clinical Progress and Strategic Partnerships
Buy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113
Protagonist Therapeutics Analyst Ratings
Strong Buy Rating for Protagonist Therapeutics on JNJ-2113's Promising Psoriasis Treatment Efficacy and Financial Outlook
Protagonist Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
Analysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)
Protagonist Therapeutics Earns 'Buy' Rating: Promising Clinical Advances and Strategic Partnerships
Buy Rating on Protagonist Therapeutics: Strategic Takeda Partnership and Rusfertide's Market Potential
Buy Rating Affirmed for Protagonist Therapeutics Following Strategic Takeda Collaboration and Promising Drug Pipeline
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and Protagonist Therapeutics (PTGX)
Buy Rating on Protagonist Therapeutics: Anticipating Rusfertide Success and Strategic Acquisition Upside